Advertisement
Alcon
Subscribe to Alcon

The Lead

Novartis Takes Control of Alcon

August 26, 2010 4:34 am | News | Comments

GENEVA (AP) — Novartis AG says it has completed its purchase of Nestle SA's 77 percent stake in eye care firm Alcon Inc. at a total cost of $38.7 billion.

Alcon Profit Climbs 8 Percent in Fourth Quarter

February 12, 2010 8:57 am | News | Comments

NEW YORK (AP) — Eye-care products company Alcon Inc. on Thursday said its fourth-quarter earnings...

Panel of Alcon Directors Rejects Novartis Bid

January 20, 2010 4:29 am | News | Comments

GENEVA (AP) — A panel of directors at eye-care company Alcon Inc. on Wednesday rejected as "grossly...

Alcon Purchases Rights for Two Eye Care Products From Sirion Therapeutics

January 19, 2010 3:59 am | News | Comments

Alcon announced today that it will purchase the rights in the United States for two FDA-approved...

View Sample

FREE Email Newsletter

Minority Shareholders Seek to Slow Alcon Takeover

January 11, 2010 4:02 am | News | Comments

GENEVA (AP) — The minority shareholders of eye-care products maker Alcon, Inc. have filed a class-action lawsuit to prevent Swiss pharmaceutical giant Novartis AG from completing a $39 billion takeover of the company.

Novartis Looks to Buy Out Alcon for $38.5 bln

January 4, 2010 3:39 am | News | Comments

BASEL, Switzerland (AP) — Novartis AG said Monday it plans to take over Alcon Inc. by paying $38.5 billion for the 77 percent stake it does not already own in a deal that would make it one of the biggest players in the global market for eye-care products.

NovaBay Pharmaceuticals to Receive Increase in Funding and Support From Alcon

December 17, 2009 3:48 am | News | Comments

NovaBay Pharmaceuticals, Inc., a clinical stage biopharmaceutical company creating a new class of anti-infectives for treating multi-drug resistant pathogens, announced today that effective immediately, its partner, Alcon Inc.

Advertisement

Novartis Says 3Q Profit up 1 Percent, Raises Outlook

October 22, 2009 4:10 am | News | Comments

ELIANE ENGELER Associated Press Writer GENEVA (AP) — Novartis AG posted Thursday a 1 percent increase in third-quarter net profit on strong sales of pharmaceuticals, such as its new Afinitor drug against kidney cancer, and raised its full-year outlook after the approval of its swine flu vaccines.

Alcon to Acquire Swiss Biotechnology Firm, ESBATech AG

September 14, 2009 4:26 am | News | Comments

Alcon has entered into a definitive agreement to acquire ESBATech AG, a Swiss biotechnology company.

Bausch & Lomb Beats Back Lens-Cleaner Lawsuits

August 31, 2009 11:42 am | News | Comments

BEN DOBBIN AP Business Writer ROCHESTER, N.Y. (AP) — Bausch & Lomb Inc., rocked by the worldwide recall of its flagship contact lens solution in 2006, has beaten back scientific claims blaming ReNu with MoistureLoc cleaner for a flurry of non-fungal eye infections.

Bausch & Lomb Settles 600 Eye Fungus Lawsuits

June 1, 2009 5:21 am | News | Comments

BEN DOBBIN AP Business Writer ROCHESTER, N.Y. (AP) — Contact lens maker Bausch & Lomb Inc. had an overriding reason for going private in 2007: It wanted to handle a devastating recall of its flagship lens cleaner, its chief executive said, "without a lot of outside distraction.

Novartis Posts 14% drop in 1Q profit

April 23, 2009 4:26 am | News | Comments

ALEXANDER G. HIGGINS Associated Press Writer GENEVA (AP) — Pharmaceuticals maker Novartis AG reported Thursday a 14 percent decline in first-quarter net profit in part due to shifts in currency values as well as the cost of financing its takeover of the Alcon eye care company.

Advertisement

NovaBay and Galderma Enter Into Global Agreement to Develop and CommercializeNovaBay's Novel Aganocide Drugs for Major Dermatological Conditions

March 25, 2009 4:42 am | News | Comments

NovaBayPharmaceuticals, Inc., a mid-stage biopharmaceutical companydeveloping first-in-class anti-infective products for the treatment andprevention of a wide range of infections without causing resistance, todayannounced that it has entered into an agreement with Galderma S.A.

Roche to Take Over Genentech for $47 billion

March 12, 2009 5:48 am | News | Comments

By ALEXANDER G. HIGGINS Associated Press Writer GENEVA (AP) — Swiss pharmaceutical giant Roche said Thursday it has agreed to buy California-based Genentech for $46.8 billion in a takeover described as the largest in Swiss corporate history.

Roche to Take Vver Genentech for $47 billion

March 12, 2009 5:47 am | News | Comments

By ALEXANDER G. HIGGINS Associated Press Writer GENEVA (AP) — Swiss pharmaceutical giant Roche said Thursday it has agreed to buy California-based Genentech for $46.8 billion in a takeover described as the largest in Swiss corporate history.

Novartis Posts 62 % Rise In 4Q Net Profit

January 28, 2009 6:08 am | News | Comments

BASEL, Switzerland (AP) — Novartis AG reported a 62 percent rise in fourth quarter net profit Wednesday, helped by steady sales growth and the absence of the restructuring charges that hindered the previous year's results. The company said net income rose to $1.

NovaBay Appoints Harry F. Hixson, Jr., PhD, Former Amgen President/Chief Operating Officer to Its Board of Directors

January 20, 2009 4:38 am | News | Comments

NovaBay Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing non-antibiotic anti-infective products for the treatment or prevention of a wide range of bacterial, fungal, and viral infections, has appointed Harry F. Hixson, Jr., PhD to its Board of Directors.

Advertisement

Kevin Buehler Appointed President and CEO of Alcon; Cary Rayment to Continue as Chairman of the Board

January 9, 2009 11:17 am | News | Comments

Alcon, Inc. has announced that on April 1, 2009 Kevin Buehler will become president and chief executive officer of Alcon, Inc.

FDA Warns Companies to Stop Marketing Unapproved Ophthalmic Balanced Salt Solution Drug Products and Topical Drug Products Containing Papain

September 30, 2008 9:25 am | News | Comments

The FDA has announced that companies marketing unapproved ophthalmic balanced salt solutions (BSS) and unapproved topical drug products containing papain must stop manufacturing and marketing these products or risk enforcement action.

INTERPHEX2005 Provides Smart Solutions for Sterile Manufacturing.

December 3, 2004 6:42 am | Product Releases | Comments

By Kevin Richards, Industry Vice President, Reed Exhibitions The common bacterium, Serratia marcescens, causes the pinkish "mildew" that appears in bathrooms. Once considered to be harmless, it is now recognized as a broad host pathogen that can cause opportunistic infections.

www.alconox.com

October 22, 2004 12:37 pm | Product Releases | Comments

Critical Cleaning Detergents Company manufactures a full line of critical cleaning detergents for a wide range of hard surface cleaning applications.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading